CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 67 enrolled
Drug / intervention
CART-EGFR-IL13Ra2 Cellsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05168423
NCT05168423Phase 1Active
CompareCT.gov

Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma

University of Pennsylvania·interventional·Posted Dec 23, 2021·Updated Apr 13, 2026

In Brief

A Phase 1 clinical trial evaluating CART-EGFR-IL13Ra2 Cells for Glioblastoma. Active but no longer recruiting, targeting 67 participants across 1 site.

Detailed Summary

This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsKite Pharma (a Gilead Company)

Timeline

Phase 1Active
2022202320242025202620272028202920302031203220332034203520362037203820392040
First PostedDec 23, 2021
Enrollment StartFeb 24, 2023
Primary CompletionDec 19, 2039
TodayJul 2, 2026
Enrollment to primary: 16.8 yearsPosted 4.5 years agoPrimary completion in 13.5 years

Interventions

CART-EGFR-IL13Ra2 Cellsdrug

autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2